DARIGOLD NAMES AMY HUMPHREYS CHIEF EXECUTIVE OFFICER
Appointment Marks Return to Dairy Company for Former CFO
Humphreys succeeds
"Amy brings a proven track record in leadership with vertically integrated food businesses like Darigold, and a keen focus on business performance, responsible and sustainable resource management, value expansion, and business transformation – all critical skills as Darigold continues our transformation aimed at modernization and growth," said
Humphreys takes on the CEO role at Darigold as the company opens a new production facility in
Humphreys arrives at Darigold with a distinguished leadership career and in-depth familiarity with the company. Apart from her time at Darigold, Humphreys has held C-level executive positions in the food manufacturing and petroleum sectors, among others. She also serves as a board director for both private and publicly held companies and is on the Economic Advisory Council for the Federal Reserve Board 12th District and the Nominating Committee for CoBank, a major financial institution for farms and agricultural businesses.
She holds a Master of Business Administration degree from the University of Washington Foster School of Business, a Bachelor of Arts in Accounting and Finance from Puget Sound University and is a Certified Public Accountant in the
"Amy is the right leader for our company as we begin this important chapter," said Kuenzi. "Allan stepped in at a critical time, and we made some significant progress under his leadership – standing up
About Darigold
Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/darigold-names-amy-humphreys-chief-executive-officer-302559577.html
SOURCE Darigold, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- In HelloNation, Tax Expert Sal Julian Details Which Itemized Deductions High-Income Individuals Lose Without Knowing It
- Fractional CMO Model Targets Enterprise Value, Not Just Revenue
- Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share